Analyzing Fluidigm (NASDAQ:FLDM) & IsoPlexis (NASDAQ:ISO)

Fluidigm (NASDAQ:FLDMGet Rating) and IsoPlexis (NASDAQ:ISOGet Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.


This table compares Fluidigm and IsoPlexis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fluidigm -45.36% -40.15% -14.86%
IsoPlexis N/A N/A N/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Fluidigm and IsoPlexis, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fluidigm 0 0 1 0 3.00
IsoPlexis 0 0 4 0 3.00

Fluidigm currently has a consensus price target of $7.00, suggesting a potential upside of ∞. IsoPlexis has a consensus price target of $17.00, suggesting a potential upside of 639.13%. Given Fluidigm’s higher probable upside, research analysts plainly believe Fluidigm is more favorable than IsoPlexis.

Institutional and Insider Ownership

76.6% of Fluidigm shares are owned by institutional investors. Comparatively, 37.5% of IsoPlexis shares are owned by institutional investors. 2.9% of Fluidigm shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Fluidigm and IsoPlexis’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fluidigm $130.58 million 0.00 -$59.24 million ($0.78) N/A
IsoPlexis $17.26 million 5.20 -$81.57 million N/A N/A

Fluidigm has higher revenue and earnings than IsoPlexis.


Fluidigm beats IsoPlexis on 5 of the 9 factors compared between the two stocks.

Fluidigm Company Profile (Get Rating)

Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

IsoPlexis Company Profile (Get Rating)

IsoPlexis Corporation is a life science technology company which build solutions for development of curative medicines and personalized therapeutics. IsoPlexis Corporation is based in BRANFORD, Conn.

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with's FREE daily email newsletter.